M&A - Immunome Inc.

Form Type: DEF 14A

Filing Date: 2025-04-24

Corporate Action: Merger

Type: Update

Accession Number: 000114036125015421

Filing Summary: Immunome, Inc. invites stockholders to attend its 2025 Annual Meeting, scheduled for June 10, 2025. The meeting will be held virtually and will cover two main proposals: the election of two nominees for Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The document details the logistics of the meeting, voting instructions, and how to access proxy materials online. It also references a previous merger agreement with Morphimmune, Inc. consummated on October 2, 2023, and outlines the steps for stockholders to vote, the requirements for a quorum, and how to obtain the results of the voting post-meeting. The notice emphasizes the importance of stockholder participation and voting prior to or during the meeting.